Wissenschaftliche Arbeiten

Uzm. Dr. Harun Muğlu

59 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16868-5 Frei zugänglicher VolltextQuelle: OpenAlex

  3. Comparison of First-Line Pembrolizumab Monotherapy Versus Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Multicenter Real-World Study from Turkey

    Medicina, 2026

    DOI 10.3390/medicina62112136 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062406 PMID 41899326 Frei zugänglicher VolltextQuelle: OpenAlex

  5. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy

    Pharmaceuticals, 2026

    DOI 10.3390/ph19040587 PMID 42075843 Frei zugänglicher VolltextQuelle: OpenAlex

  6. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15083118 PMID 42074920 Frei zugänglicher VolltextQuelle: OpenAlex

  7. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

    OncoImmunology, 2026

    DOI 10.1080/2162402x.2026.2738262 PMID 42788839 Frei zugänglicher VolltextQuelle: OpenAlex

  8. Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis

    Breast Cancer Targets and Therapy, 2026

    DOI 10.2147/bctt.s647399 PMID 42936308 Frei zugänglicher VolltextQuelle: OpenAlex

  9. Real-world Efficacy and Safety of Trastuzumab Deruxtecan in HER2-positive Metastatic Breast Cancer: A Multicenter Retrospective Study from Türkiye

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-1-1 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  10. Unveiling the Uncommon: A Comprehensive Review and Case Report on Targeting Rare MET Fusions in NSCLC

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-7-10 Frei zugänglicher VolltextQuelle: OpenAlex

  11. Meme Kanseri

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852 Frei zugänglicher VolltextQuelle: OpenAlex

  12. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Therapeutic Advances in Medical Oncology, 2026

    DOI 10.1177/17588359261430583 PMID 41835339 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  13. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Quelle: OpenAlex

  14. Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026

    DOI 10.1007/s12094-026-04228-5 PMID 41670816 Quelle: Europe PMC

  15. Efficacy and Tolerability of Pazopanib in Elderly Patients with Advanced Soft Tissue Sarcoma: A Multicentre Real-World Study from Turkey

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15124803 PMID 42355971 Frei zugänglicher VolltextQuelle: ORCID

  16. Erken Evre Meme Kanserinde Tedavi Sonrası Takip

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852.c2793 Quelle: ORCID

  17. Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-47351-7 PMID 41933152 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  18. Abstract PS4-10-28: Neoadjuvant Chemoimmunotherapy in Early-Stage TNBC: Real-World Analysis of Predictors of pCR and Survival

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps4-10-28 Quelle: OpenAlex

  19. Abstract PS4-04-11: Statins enhance trastuzumab deruxtecan efficacy: Preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps4-04-11 Quelle: OpenAlex

  20. Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

    Experimental Hematology and Oncology, 2026

    DOI 10.1186/s40164-026-00787-z PMID 42260640 Frei zugänglicher VolltextQuelle: OpenAlex

  21. Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors

    Medicina, 2025

    DOI 10.3390/medicina61071279 PMID 40731908 Frei zugänglicher VolltextQuelle: OpenAlex

  22. Prognostic and Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer

    Medicina, 2025

    DOI 10.3390/medicina61030380 PMID 40142191 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  23. Clinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes: Single-Center Experience

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14072264 PMID 40217714 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  24. The Prognostic and Predictive Roles of Ataxia–Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy

    Diagnostics, 2025

    DOI 10.3390/diagnostics15081048 PMID 40310425 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  25. Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14092937 PMID 40363968 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  26. Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: Tek merkez deneyimi

    Ege Tıp Dergisi, 2025

    DOI 10.19161/etd.1569835 Frei zugänglicher VolltextQuelle: OpenAlex

  27. Kanserde Takip

    Akademisyen Kitabevi eBooks, 2025

    DOI 10.37609/akya.3716 Frei zugänglicher VolltextQuelle: OpenAlex

  28. The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14186536 PMID 41010740 Frei zugänglicher VolltextQuelle: OpenAlex

  29. The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2− Breast Cancer: A Multicenter Observational Study from Turkey

    Cancers, 2025

    DOI 10.3390/cancers17091592 PMID 40361516 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  30. Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis

    Medicina, 2025

    DOI 10.3390/medicina61010123 PMID 39859105 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  31. HER2 POZITIF METASTATIK MEME KANSERLI HASTALARDA TRASTUZUMAB DERUXTECAN’IN GERÇEK YAŞAM VERILERI: TÜRK ONKOLOJI GRUBU ÇOK MERKEZLI ÇALIŞMASI

    Kocaeli Üniversitesi - AVESİS, 2025

    Quelle: OpenAlex

  32. Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70165 PMID 40968962 1 Zitation (Europe PMC) Quelle: OpenAlex

  33. The Prognostic Role of Systemic Inflammatory Markers Before Abiraterone/Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer

    2025

    DOI 10.20944/preprints202508.0265.v1 Frei zugänglicher VolltextQuelle: ORCID

  34. The Prognostic and Predictive Role of ATM Expression in Patients with Metastatic Non-Small Cell Lung Cancer Receiving Pembrolizumab Monotherapy or Combination with Chemotherapy

    2025

    DOI 10.20944/preprints202503.1873.v1 Frei zugänglicher VolltextQuelle: ORCID

  35. Clinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes- Single-Center Experience

    2025

    DOI 10.20944/preprints202503.0015.v1 Frei zugänglicher VolltextQuelle: ORCID

  36. Prognostic Value of Claudin 18.2, Isocitrate Dehydrogenase-1, and Neutrophil-to-Lymphocyte Ratio in Unresectable Pancreatic Ductal Adenocarcinoma

    2025

    DOI 10.20944/preprints202502.1220.v1 Frei zugänglicher VolltextQuelle: ORCID

  37. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

    Cancers, 2025

    DOI 10.3390/cancers18010101 PMID 41514612 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  38. Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach

    Cancers, 2025

    DOI 10.3390/cancers17020233 PMID 39858018 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  39. Tükürük Bezi Kanserleri

    Akademisyen Kitabevi eBooks, 2025

    DOI 10.37609/akya.3716.c6041 Quelle: ORCID

  40. The Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer: A Multicenter Real-World Study from Turkey

    2025

    DOI 10.20944/preprints202504.0284.v1 Frei zugänglicher VolltextQuelle: ORCID

  41. Unveiling the Uncommon: Targeting Rare MET Fusions in NSCLC: A Comprehensive Review

    2025

    DOI 10.20944/preprints202503.0423.v1 Frei zugänglicher VolltextQuelle: ORCID

  42. Acute Kidney Injury Secondary to Abdominal Compartment Syndrome: Biomarkers, Pressure Variability, and Clinical Outcomes

    Medicina, 2025

    DOI 10.3390/medicina61030383 PMID 40142193 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  43. Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review

    Medicina, 2025

    DOI 10.3390/medicina61020302 PMID 40005418 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  44. Acute Kidney Injury Secondary to Abdominal Compartment Syndrome: Biomarkers, Pressure Variability, and Clinical Outcomes

    2025

    DOI 10.20944/preprints202502.0315.v1 Frei zugänglicher VolltextQuelle: ORCID

  45. Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler - Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim

    Akademisyen Kitabevi eBooks, 2024

    DOI 10.37609/akya.2380 Frei zugänglicher VolltextQuelle: OpenAlex

  46. Torasik Rayoterapi Sonrası Gelişen Radyasyon Pnömoniti Hastalarında Prognostik ve Prediktif Faktörlerin Analizi: Retrospektif Tek Merkez Deneyimi

    Ege Tıp Bilimleri Dergisi, 2024

    DOI 10.33713/egetbd.1527615 Frei zugänglicher VolltextQuelle: OpenAlex

  47. Prognostic And Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer

    2024

    DOI 10.20944/preprints202412.2244.v1 Frei zugänglicher VolltextQuelle: ORCID

  48. Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis

    2024

    DOI 10.20944/preprints202412.2185.v1 Frei zugänglicher VolltextQuelle: ORCID

  49. Immunotherapy in Lung and Thoracic Cancer

    2024

    DOI 10.69860/nobel.9786053359388.12 Quelle: ORCID

  50. Late Onset Myocarditis Following Immune Checkpoint Inhibitor Therapy: A Case Series with Literature Review

    2024

    DOI 10.20944/preprints202412.2304.v1 Frei zugänglicher VolltextQuelle: ORCID